FDA
-
-
-
-
-
-
-
Propanc Biopharma signs MOU with Avance Clinical for Phase 1 trial
-
-
-
-
-
-
-
Propanc Biopharma plans phase 1b trial for cancer therapy PRP in 2026
-
-
-
-
-
-
-
Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office
-
-
-
-
-
-
-
Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors
-
-
-
-
-
-
-
Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer
-
-
-
-
-
-
-
Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade
-
-
-
-
-
-
-
Propanc Biopharma Believes PRP Reduced Toxicity Will Impact Cancer Patient Lives Significantly
-
328,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

